Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Illumina, Inc. — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $69.4 (market cap $30.93B), while Illumina, Inc. trades at $271.46 (market cap $41.04B). The key difference: Illumina, Inc. is the larger of the two by market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| GEHC | ILMN | |
|---|---|---|
Market Cap | $30.93B | $41.04B |
Volume | 5,033,451 | 2,120,523 |
Sector | Health | Health |
52-Week High | $88.16 | $293.69 |
52-Week Low | $59.48 | $93.00 |
Enterprise Value | $39.39B | $42.39B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 84 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Illumina (ILMN) trades at $271.18, down 1.99% but near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Revenue remains stable at $4.3B with impressive profitability metrics including 66.4% gross margin and 18.3% net income margin. Recent news highlights S&P 500 inclusion and AI-driven growth initiatives.
ILMN presents a mixed outlook with strong fundamentals and technical momentum offset by premium valuations (P/E 50.6). The primary opportunity lies in genomic sequencing leadership and AI integration, while risks include valuation sensitivity and competitive pressures. Analyst consensus leans bullish with 54% buy ratings but a $241 price target suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
